Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018129 | 0.84 | CYP1A2 (0.43) | KHKARALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL23860793 | 0.84 | KHK (0.53) | KHKARALDH1A1NOTUM | |
| SCHEMBL21977692 | 0.84 | CYP1A2 (0.43) | KHKARALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL23860827 | 0.84 | KHK (0.62) | KHKSMN1; SMN2ARALDH1A1CYP1A2 | |
| SCHEMBL566209 | 0.79 | KHK (0.57) | KHKSMN1; SMN2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL10853416 | 0.79 | PIK3CD (0.40) | ALDH1A1NOTUM | |
| SCHEMBL25983144 | 0.74 | AR (0.53) | AR | |
| SCHEMBL2724202 | 0.74 | AR (0.48) | AR | |
| SCHEMBL165776 | 0.74 | KHK (0.69) | KHKSMN1; SMN2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL29448447 | 0.74 | KHK (0.69) | KHKSMN1; SMN2ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| US-9499570-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-9145429-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-8716478-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2011094450-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20080312185-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | CHEN ZHIDONG | 2008-12-18 | — | — | US | disclosed |
| US-20060270671-A1 | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7119102-B2 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1692141-A1 | SUBSTITUTED 3-AMINO-THIENO¬2,3-B| PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AS IKK INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050182053-A1 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005056562-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-B] PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AS IKK INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182053-A1 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKG, IKBKE | KHK 719/4885SMN1; SMN2 3793/4885AR 2188/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | KHK 4005/4885SMN1; SMN2 1252/4885AR 3619/4885 |
| US-20060270671-A1 | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | CPS1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TK2 | KHK 604/4885SMN1; SMN2 1808/4885AR 878/4885 |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | KHK 4877/4885SMN1; SMN2 1603/4885AR 3799/4885 |
| US-20080312185-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | CPS1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TK2 | KHK 604/4885SMN1; SMN2 1808/4885AR 878/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | KHK 4089/4885SMN1; SMN2 1757/4885AR 1680/4885 |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | KHK 4877/4885SMN1; SMN2 1603/4885AR 3799/4885 |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | KHK 4877/4885SMN1; SMN2 1603/4885AR 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.